PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Institute of Cancer Research, 15 Cotswold Road, Sutton, London, SM2 5NG, UK.\', \'Evotec, 114 Innovation Dr, Milton Park, Abingdon, OX14 4RZ, UK.\', \'National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Hertfordshire, EN6 3QG, UK.\', \'Institute of Cancer Research, 15 Cotswold Road, Sutton, London, SM2 5NG, UK. terry.rabbitts@icr.ac.uk.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1038/s41598-021-89887-w
?:hasPublicationType
?:journal
  • Scientific reports
is ?:pmid of
?:pmid
?:pmid
  • 34006961
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.533
?:rankingScore_hIndex
  • 122
is ?:relation_isRelatedTo_publication of
?:title
  • Implementing a method for engineering multivalency to substantially enhance binding of clinical trial anti-SARS-CoV-2 antibodies to wildtype spike and variants of concern proteins.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34006961>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34006961>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all